TriVisc (sodium hyaluronate) / OrthogenRx, Meiji Seika - LARVOL DELTA

A new hyaluronate gel spacer and injection technique for cervical cancer brachytherapy: a technical report. (PubMed, J Radiat Res) - "We introduce a new hyaluronate gel spacer with MEIJI (ADANT®) as an alternative to the previously used Suvenyl® and its injection technique for cervical cancer brachytherapy. MEIJI HGI facilitates a sufficient CTVHRD90% while keeping the rectal and bladder D2cc within dose constraints, even when the rectum and bladder are in close proximity to the CTVHR. In conclusion, the MEIJI spacer may help appropriately meet dose constraints, thereby potentially contributing to improving local control and/or reducing adverse events for patients receiving radiotherapy for cervical cancer."

Journal • Cervical Cancer • Oncology • Solid Tumor

Impact of intra-articular high-concentration hyaluronic acid administration on the innate immune response in experimental knee osteoarthritis. (PubMed, BMC Musculoskelet Disord) - "Intra-articular administration of high concentrations of HA reduced IL-1β concentration in the OA synovium despite no observable improvement in cartilage or synovial lesions was observed. We suggest that the long-term beneficial effect of HA in human OA could be attributed to a "memory fingerprint" in the innate immune response, potentially leading to sustained reduced activity over an extended period of treatment."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • IL1B

Efficacy and Safety of One Shot of Hyaluronic Acid in Hip Osteoarthritis: Postmarketing Clinical Follow-Up for Real-World Evidence. (PubMed, Open Access Rheumatol) - "An observational, cross-sectional and retrospective study was conducted in a cohort of patients with hip OA treated with a single injection of HA (Adant One, Meiji Pharma Spain, Spain) from January 2021 to December 2022...A single injection of IA HA significantly improved pain and function in patients with hip OA. These findings support the use of viscosupplementation for hip OA management and underscore the need for further studies to confirm these results and assess the long-term benefits of IA HA in hip OA."

HEOR • Journal • P4 data • Real-world • Real-world evidence • Immunology • Osteoarthritis • Pain • Rheumatology

Navigating the New EU Medical Devices Regulation: Retrospective Post-Market Follow-Up of Hyaluronic Acid Injections for Knee Osteoarthritis. (PubMed, Open Access Rheumatol) - "The administration of a Adant® One single intra-articular hyaluronic acid injection in knee osteoarthritis is effective, safe, and maintains the improvement over a six-month period. Our findings also emphasize the need of using standardized tools for accurate efficacy assessment and optimal patient care."

Journal • P4 data • Retrospective data • Immunology • Osteoarthritis • Pain • Rheumatology

Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee (clinicaltrials.gov) - P=N/A | N=446 | Completed | Sponsor: Tedec-Meiji Farma, S.A. | Phase classification: P4 ➔ P=N/A

Phase classification • Immunology • Osteoarthritis • Pain • Rheumatology

OrthogenRx Debuts HARMOKNEE Customer Support Services at American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting (PRNewswire) - "OrthogenRx...announced it will showcase its new platform HARMOKNEE™ Customer Support Services, at the 2021 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in San Diego, CA August 31- September 3, 2021....The HARMONKEE platform provides simplified options for healthcare professionals and patients to access OrthogenRx Hyaluronic Acid (HA) products, TriVisc® and GenVisc® 850, that are used to improve joint lubrication and cushioning to treat knee pain due to osteoarthritis (OA) in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen....HARMOKNEE includes support services that streamline the prescribing and reimbursement process at no charge; making it easier for OrthogenRx customers to obtain prior authorization forms for insurance specific plans and initiate benefits investigations." "

Clinical • Reimbursement • CNS Disorders • Osteoarthritis • Pain

OrthogenRx Announces 2020 Achievements (PRNewswire) - "OrthogenRx...today announced its company highlights for 2020 which have exceeded revenue targets. Among many accomplishments, OrthogenRx is proud to have launched new pricing options to facilitate access to affordable healthcare products, needed more than ever during the health and financial crisis of 2020...Launched TriVisc® Direct Purchase Program to provide greater access to TriVisc and a convenient solution for patients without insurance coverage."

Reimbursement • CNS Disorders • Osteoarthritis • Pain